AVXL · Insider Trading
Anavex Life Sciences
Every open-market purchase and sale reported by AVXL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-28 | Sandra Boenisch | PFO & Treasurer | A | +95,000 deriv. | — |
| 2026-01-09 | Sandra Boenisch | PFO & Treasurer | A | +12,500 deriv. | — |
| 2026-01-09 | Christopher U Missling | President and CEO | A | +125,000 deriv. | — |
| 2025-10-03 | Christopher U Missling | President and CEO | A | +125,000 deriv. | — |
| 2025-10-03 | Sandra Boenisch | PFO & Treasurer | A | +12,500 deriv. | — |
| 2025-09-12 | Christopher U Missling | President and CEO | MIXED | +42,452 | −$444.56K |
| 2025-08-22 | Sandra Boenisch | PFO & Treasurer | A | +12,500 deriv. | — |
| 2025-08-22 | Christopher U Missling | President and CEO | A | +125,000 deriv. | — |
| 2025-06-09 | Steffen Thomas | Director | MIXED | +38,651 | +$45 |
| 2025-04-30 | Christopher U Missling | President and CEO | A | +125,000 deriv. | — |
| 2025-04-30 | Sandra Boenisch | PFO & Treasurer | A | +12,500 deriv. | — |
| 2025-04-02 | Peter D.O. Donhauser | Director | A | +50,000 deriv. | — |
| 2025-04-02 | Jiong Ma | Director | A | +50,000 deriv. | — |
| 2025-04-02 | Athanasios Skarpelos | Director | A | +50,000 deriv. | — |
| 2025-04-02 | Claus Vander Velden | Director | A | +50,000 deriv. | — |
| 2025-04-02 | Steffen Thomas | Director | A | +50,000 deriv. | — |
| 2025-03-26 | Christopher U Missling | President and CEO | MIXED | +217,503 | −$2.26M |
| 2025-01-17 | Sandra Boenisch | PFO & Treasurer | A | +12,500 deriv. | — |
| 2025-01-17 | Christopher U Missling | President and CEO | A | +291,666 deriv. | — |
| 2024-12-23 | Sandra Boenisch | PFO & Treasurer | A | +12,500 deriv. | — |
| 2024-12-23 | Christopher U Missling | President and CEO | A | +125,000 deriv. | — |
| 2024-12-06 | Sandra Boenisch | PFO & Treasurer | A | +10,000 deriv. | — |
| 2024-12-06 | Christopher U Missling | President and CEO | A | +125,000 deriv. | — |
| 2024-06-17 | Peter D.O. Donhauser | Director | Buy | +2,835 | +$10.32K |
| 2024-05-17 | Steffen Thomas | Director | Buy | +5,000 | +$22.60K |
| 2024-04-01 | Christopher U Missling | President and CEO | MIXED | — | −$278.11K |
| 2024-02-23 | Steffen Thomas | Director | A | +50,000 deriv. | — |
| 2024-02-23 | Claus Vander Velden | Director | A | +50,000 deriv. | — |
| 2024-02-23 | Athanasios Skarpelos | Director | A | +50,000 deriv. | — |
| 2024-02-23 | Peter D.O. Donhauser | Director | A | +50,000 deriv. | — |
| 2024-02-23 | Jiong Ma | Director | A | +50,000 deriv. | — |
| 2024-01-12 | Christopher U Missling | President and CEO | A | −125,000 deriv. | — |
| 2024-01-12 | Sandra Boenisch | PFO & Treasurer | A | +10,000 deriv. | — |
| 2023-06-30 | Christopher U Missling | President and CEO | MIXED | +232,000 | −$1.34M |
| 2023-04-04 | Jiong Ma | Director | A | +50,000 deriv. | — |
| 2023-04-04 | Athanasios Skarpelos | Director | A | +50,000 deriv. | — |
| 2023-04-04 | Steffen Thomas | Director | A | +50,000 deriv. | — |
| 2023-04-04 | Claus Vander Velden | Director | A | +50,000 deriv. | — |
| 2023-04-04 | Peter D.O. Donhauser | Director | A | +50,000 deriv. | — |
| 2022-06-29 | Peter D.O. Donhauser | Director | A | +50,000 deriv. | — |
| 2022-06-29 | Steffen Thomas | Director | A | +50,000 deriv. | — |
| 2022-06-29 | Claus Vander Velden | Director | A | +50,000 deriv. | — |
| 2022-06-29 | Jiong Ma | Director | A | +50,000 deriv. | — |
| 2022-06-29 | Athanasios Skarpelos | Director | A | +50,000 deriv. | — |
| 2022-05-27 | Athanasios Skarpelos | Director | MIXED | — | −$407.00K |
| 2021-08-04 | Sandra Boenisch | PFO and Treasurer | A | +40,000 deriv. | — |
| 2021-08-04 | Steffen Thomas | Director | A | +25,000 deriv. | — |
| 2021-08-04 | Christopher U Missling | Chief Executive Officer | A | +500,000 deriv. | — |
| 2021-08-04 | Jiong Ma | Director | A | +25,000 deriv. | — |
| 2021-08-04 | Athanasios Skarpelos | Director | A | +25,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Christopher U Missling | President and CEO | 1,510,165 | $1.93M |
| Athanasios Skarpelos | Director | 1,356,458 | $1.74M |
| Sandra Boenisch | PFO & Treasurer | 47,963 | $61.39K |
| Steffen Thomas | Director | 43,651 | $55.87K |
| Peter D.O. Donhauser | Director | 5,000 | $6.40K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AVXL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.